VATICAN CITY, ROME – Newsaktuell – 9 October 2025 – Domino’s Pizza caused a sensation in Italy with its “Pardoned Pineapple Pizza” campaign: An employee carried a pineapple pizza through the Holy Door of St. Peter’s Basilica – a door that is only opened once every 25 years. Those who pass through it are freed … Read more
SAN JOSE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) — Today, Zoom Communications, Inc. (NASDAQ: ZM) announced that Zoom Phone, its AI-first, cloud phone system, recently surpassed 10 million seats globally, marking a major milestone in the company’s mission to modernize business communications. Since its launch in 2019, Zoom Phone has become one of the fastest-growing cloud telephony … Read more
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings […]
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has … Read more
